SCHEMBL7812949

SCHEMBL7812949

Cc1ccc(N2CCCC2=O)cc1Br

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
KMT2A Q03164 5/20 0.51
ALDH1A1 P00352 3/20 0.51
KDM4E B2RXH2 1/20 0.51
PKM P14618 2/20 0.50
HSD17B10 Q99714 1/20 0.50
BRD9 Q9H8M2 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
HPGD P15428 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MEN1 O00255 4/20 0.46
TSHR P16473 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8144111 0.87 LMNA (0.57) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL30731240 0.87 LMNA (0.57) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL12051770 0.85 PKM (0.60) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL30104761 0.82 HSD17B10 (0.59) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL7816315 0.82 ALDH1A1 (0.56) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL7548885 0.82 HSD17B10 (0.59) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL6028329 0.82 HSD17B10 (0.59) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL31704180 0.81 ALDH1A1 (0.49) LMNAKMT2AALDH1A1KDM4EBRD9
SCHEMBL12062757 0.81 KMT2A (0.51) LMNAKMT2AALDH1A1KDM4EPKM
SCHEMBL7806456 0.81 BRD9 (0.53) LMNAKMT2AALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 WO disclosed
EP-1119547-A1 SUBSTITUTED PYRROLIDINONE, THIAZOLIDINONE OR OXAZOLIDINONE AS HERBICIDES Syngenta Limited (GB) 2001-08-01 EP disclosed
WO-2000021928-A1 SUBSTITUTED PYRROLIDINONE, THIAZOLIDINONE OR OXAZOLIDINONE AS HERBICIDES SYNGENTA LIMITED (GB) 2000-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 LMNA 1117/4885KMT2A 3804/4885ALDH1A1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.